Alirocumab (anti-PCSK9) - HY-P9928A
Nur noch %1 verfügbar
Catalog #
HY-P9928A
Ab
439,00 €
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation[1][2][3][4][5][6][7][8][9][10][11].
| Datasheet URL | http://file.medchemexpress.com/batch_PDF/HY-P9928A/Alirocumab-anti-PCSK9-DataSheet-MedChemExpress.pdf |
|---|---|
| Shipping | Dry Ice |
| Application | Neuroscience-Neuromodulation |
| Alternative Names | REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9) |
| CAS | 1245916-14-6 |
| Storage | Store at -80°C for 2 years |
| MWT | N/A |
| Solubility | H2O |
| Clinical Information | Phase 4 |
| Target | CX3CR1;HMG Family;Keap1-Nrf2;NF-κB;NOD-like Receptor (NLR);PCSK9 |
| Application: | Neuroscience-Neuromodulation |
|---|